Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT04788043 · Ranjana Advani · PHASE2 · terminated · last registry update 2026-06-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Discontinuation of magrolimab development” | – | Registry record, Ranjana Advani |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD47 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-03Also stopped (terminated): University of Colorado, Denver, Evorpacept (ALX148) + Cetuximab (NCT05167409)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-22Results posted on the registry: University of Colorado, Denver, Evorpacept (ALX148) + Cetuximab (NCT05167409)
- 2026-06-30Also stopped (terminated): National Cancer Institute (NCI), Dinutuximab + Magrolimab (NCT04751383)
- 2026-04-23Results posted on the registry: M.D. Anderson Cancer Center, Azacitidine + Magrolimab (NCT04435691)
- 2026-04-23Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Magrolimab (NCT04435691)
- 2026-01-21Results posted on the registry: National Cancer Institute (NCI), Dinutuximab + Magrolimab (NCT04751383)
- 2025-11-19Results posted on the registry: Gilead Sciences, Magrolimab + Pembrolizumab (NCT04854499)
- 2025-11-19Also stopped (terminated): Gilead Sciences, Magrolimab + Pembrolizumab (NCT04854499)
- 2025-11-04Also stopped (terminated): Gilead Sciences, Magrolimab + Nab-Paclitaxel (NCT04958785)
- 2025-10-22Results posted on the registry: M.D. Anderson Cancer Center, Pembrolizumab + Magrolimab (NCT06046482)
- 2025-10-22Also stopped (terminated): M.D. Anderson Cancer Center, Pembrolizumab + Magrolimab (NCT06046482)
- 2025-10-16Results posted on the registry: National Cancer Institute (NCI), Magrolimab + Mogamulizumab (NCT04541017)
- 2025-10-16Also stopped (terminated): National Cancer Institute (NCI), Magrolimab + Mogamulizumab (NCT04541017)
- 2025-10-03Results posted on the registry: Gilead Sciences, Magrolimab + Nab-Paclitaxel (NCT04958785)
- 2025-07-20Also stopped (terminated): ALX Oncology Inc., evorpacept + azacitidine (NCT04417517)
- 2025-07-01Results posted on the registry: Gilead Sciences, Magrolimab + Bevacizumab (NCT05330429)
- 2025-07-01Also stopped (terminated): Gilead Sciences, Magrolimab + Bevacizumab (NCT05330429)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision